X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous humor.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Catiolanze
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of mild to moderate glaucoma.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: PA5108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 22, 2022
Details:
IYUZEH™ is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free. IYUZEH™ is formulated without any of the preservatives commonly used in topical ocular preparations, including benzalkonium chloride (BAK).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 22, 2022
Details:
TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial, will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: TC-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 22, 2022
Details:
Phase IIa study met primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort, demonstrating a potential significant benefit of the PA5108 Ocular Implant designed to treat patients with glaucoma by enabling a constant dose of medication.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: PA5108
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2022
Details:
TC-002 (latanoprost) is a prostaglandin F2 alpha agonist developed by a novel investigational platform through which topical ophthalmic solutions are preserved in a patient-friendly multi-dose bottle but are delivered to the ocular surface as preservative-free.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: TC-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
Netarsudil 0.02% is known by the name Rhokiinsa® in the European Union, where it is approved for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
TearClear is the first and only company to develop products that keep BAK preserved formulations safely in the bottle and deliver pristine, preservative free drops. Latanoprost is used to treat high pressure inside the eye due to glaucoma or other eye disease.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: TC-002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
The study was designed in accordance with the requirements of Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) to support a potential regulatory submission of netarsudil ophthalmic solution in Japan.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
European Commission has granted a marketing authorisation for Roclanda® 0.02%/0.005% for high intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil are insufficient for IOP reduction.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
TC-002 (latanoprost) is a prostaglandin F2 alpha agonist developed by a novel investigational platform through which topical ophthalmic solutions are preserved in a patient-friendly multi-dose bottle but are delivered to the ocular surface as preservative-free.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: TC-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months.
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Xalatan
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Aerie Pharmaceuticals successful interim 90-day topline data from its six-month Phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda® to Ganfort®.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
